CJC-1295 and Ipamorelin Peptide Blend

Ipamorelin and CJC-1295 are both classified as growth hormone secretagogues, peptides believed to promote endogenous growth hormone (GH) release. Ipamorelin is a synthetic pentapeptide, while CJC-1295 is composed of 29 amino acids. Ipamorelin is categorized as a growth hormone secretagogue (GHS), meaning it stimulates GH release without being a GHRH analog itself. Conversely, CJC-1295 mimics the natural growth hormone-releasing hormone (GHRH) and is studied for its potential to trigger GH secretion. Both peptides are grouped in research for their similar roles, differing mainly in half-life and pharmacokinetic behavior.

Overview

The combination of CJC-1295 and Ipamorelin is suggested to elevate growth hormone levels by acting on the anterior pituitary gland, which may then release GH naturally, potentially maintaining higher circulating levels.

CJC-1295 is a tetrasubstituted version of GHRH (1-29), representing the shortest functional fragment of GHRH. This 29-amino-acid peptide may stimulate somatotroph cells in the pituitary gland to produce growth hormone. Four amino acids within the sequence—at positions 2, 8, 15, and 27—are substituted, which may enhance resistance to enzymatic degradation and improve peptide activity. These modifications could allow binding to plasma proteins such as albumin, with small interactions also possible with fibrinogen and immunoglobulin G (IgG), effectively extending the peptide’s half-life from approximately 10 minutes to 30 minutes and potentially increasing plasma GH and insulin-like growth factor 1 (IGF-1) levels.

When CJC-1295 is combined with a drug affinity complex (DAC), the peptide may bind more effectively to plasma proteins. Specifically, DAC involves attaching an N-epsilon-3-maleimidopropionamide lysine derivative to the C-terminal end. This modification improves pharmacokinetics while retaining strong receptor affinity similar to natural GHRH, with studies showing the peptide detectable in plasma for over 72 hours.

Ipamorelin, also known as NNC 26-0161, is a synthetic pentapeptide that interacts with growth hormone secretagogue receptors (GHS-R1a) primarily located in the hypothalamus. These receptors, often referred to as ghrelin receptors, mediate GH release from somatotroph cells. Ipamorelin is considered highly selective, stimulating GH secretion without significantly affecting other pituitary hormones, such as prolactin.

When used together, the CJC-1295 and Ipamorelin blend, often called a peptide stack, demonstrates complementary effects. Ipamorelin initiates GH release within the first two hours, while CJC-1295 provides sustained GH secretion as Ipamorelin’s effect declines, creating a synergistic release pattern.

Chemical Makeup

• Molecular Formula:
   - CJC-1295: C152H252N44O42
   - Ipamorelin: C38H49N9O5

• Molecular Weight:
   - CJC-1295: 3367.9 g/mol
   - Ipamorelin: 711.8 g/mol

• Other Known Titles:
   - CJC-1295: CJC-1295 NO DAC; Mod GRF 1-29
   - Ipamorelin: NNC 26-0161